DMII (Drugs Made In America Acquisition II) Moat Score: 1/10 (As of Jul. 11, 2026)


DMII Drugs Made In America Acquisition II Corp DMII
15 GF Score
Price $10.10
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition II Moat Score?

Drugs Made In America Acquisition II DMII 15 Moat Score is 1 as of Jul. 11, 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 583 Diversified Financial Services companies, Drugs Made In America Acquisition II ranks better than 87.31% on this metric.

Drugs Made In America Acquisition II has the Moat Score of 1, which implies that the company might have No Moat - Very weak/transient advantages.

Drugs Made In America Acquisition II has No Moat: As a SPAC, Drugs Made In America Acquisition II Corp does not possess inherent competitive advantages. It lacks market leadership, intellectual property, or established customer loyalty.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Drugs Made In America Acquisition II might have No Moat - Very weak/transient advantages.

Drugs Made In America Acquisition II  (NAS:DMII) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Drugs Made In America Acquisition II Moat Score Related Terms

DMII vs BCSS, EVAC, CEPF: Moat Score Comparison

For the Shell Companies subindustry, Drugs Made In America Acquisition II's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Drugs Made In America Acquisition II Moat Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition II's Moat Score distribution charts can be found below:

* The bar in red indicates where Drugs Made In America Acquisition II's Moat Score falls into.


DMII
15GF Score
Drugs Made In America Acquisition II Corp DMII
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 1 mean?
Drugs Made In America Acquisition II (DMII) has a Moat Score of 1 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Drugs Made In America Acquisition II ranks #74 out of 583 companies in the Diversified Financial Services industry, placing it in the top 12.7%.
Is Drugs Made In America Acquisition II's Moat Score too high?
Drugs Made In America Acquisition II's current Moat Score is 1. Based on the distribution chart, Drugs Made In America Acquisition II ranks #74 out of 583 companies in the Diversified Financial Services industry, which is in the top quartile — a strong position relative to peers. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's Moat Score compare to BCSS and EVAC?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition II ranks #74 out of 583 companies for Moat Score. This places Drugs Made In America Acquisition II in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Diversified Financial Services company?
A good Moat Score depends on the Diversified Financial Services industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Drugs Made In America Acquisition II's current Moat Score is 1. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current Moat Score of 1. The current Moat Score is 1. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current Moat Score is 1 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
15GF Score

Get the complete analysis for DMII

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.10
Price